|
TES expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.40519999975086E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.55119999999398E-05 |
| Normal-vs-Stage2 |
1.68724999999315E-05 |
| Normal-vs-Stage3 |
1.99929999999959E-07 |
| Normal-vs-Stage4 |
2.48109999989587E-07 |
| Stage1-vs-Stage2 |
2.015600E-01 |
| Stage1-vs-Stage3 |
5.155500E-02 |
| Stage1-vs-Stage4 |
1.449690E-02 |
| Stage2-vs-Stage3 |
8.579800E-01 |
| Stage2-vs-Stage4 |
5.122000E-01 |
| Stage3-vs-Stage4 |
5.981200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.95440000031411E-07 |
| Normal-vs-AfricanAmerican |
2.599300E-03 |
| Normal-vs-Asian |
2.628000E-04 |
| Caucasian-vs-AfricanAmerican |
5.663200E-01 |
| Caucasian-vs-Asian |
5.605200E-01 |
| AfricanAmerican-vs-Asian |
9.163400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.10169999976296E-07 |
| Normal-vs-Female |
1.36950000007019E-07 |
| Male-vs-Female |
9.300600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.390900E-04 |
| Normal-vs-Age(41-60Yrs) |
2.09720000254876E-08 |
| Normal-vs-Age(61-80Yrs) |
3.04750003010668E-09 |
| Normal-vs-Age(81-100Yrs) |
8.576300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.650300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.902620E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.791200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.173200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.894000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.643600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.040400E-01 |
| Classical-VS-Follicular |
2.581900E-04 |
| Classical-VS-Other |
8.911800E-01 |
| Classical-VS-Normal |
2.30709999999856E-05 |
| Tall-VS-Follicular |
3.727200E-01 |
| Tall-VS-Other |
5.568600E-01 |
| Tall-VS-Normal |
3.83270000000602E-05 |
| Follicular-VS-Other |
3.726600E-01 |
| Follicular-VS-Normal |
5.31799999592408E-08 |
| Other-VS-Normal |
1.749960E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.76490000006291E-07 |
| Normal-vs-N1 |
8.247200E-04 |
| N0-vs-N1 |
3.283800E-01 |
|
|
